^
Association details:
| Biomarker: | EGFR exon 20 insertion + EGFR amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer
Excerpt:
Among 24 patients administered an EGFR-TKI, median PFS was longer in the non-EGFR amplification group than in the EGFR amplification group (110 vs. 31 days, P=0.030).
DOI:
10.21037/jtd-20-1630
